Report on Operations 2014

XVIVO Perfusion AB (publ)

XVIVO Perfusion is a medical technology company which develops solutions and systems for assessing the usability of organs, enabling the treatment of organs and maintaining organs in good condition outside the body pending transplantation. Currently, the company's product Perfadex® has a market share of more than 90 percent in the traditional preservation of lungs for transplantation. The company's products XPS™ and STEEN Solution™ for warm perfusion have regulatory approval in all major markets.

XVIVO Perfusion employs 11 people at its headquarters in Gothenburg, Sweden, and five at its office for North & South America in Denver, USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. The Certified Adviser is Redeye, www.redeye.se.

XVIVO PERFUSION

Strong growth and doubled EBITDA exklusive one-time expenses

FOURTH QUARTER 2014 (OCT - DEC)

- Net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding to an increase of 28 percent.
- Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 5.9 (3.0) million, corresponding to an EBITDA margin of 23 percent. One-time expenses of SEK 2.8 million related to the dispute regarding three Vivoline patents/patent applications have been charged against the quarter.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.1 (3.0) million, corresponding to an EBITDA margin of 12 percent.
- Net income amounted to SEK -0.3 (2.4) million, resulting in earnings per share of SEK -0.01 (0.12).
- Cash flow from operating activities was SEK -5.4 (7.1) million due to increased working capital effecting cash flow with by -7.8 SEK million.
- Net sales for consumables in the quarter amounted to SEK 25.5 (20.0) million, corresponding to an increase of 28 percent in SEK. Sales for consumables increased by 17 percent in local currency.
- Products for warm perfusion (STEEN Solution™ and products related to the use of the XPS™) accounted for 34 (21) percent of the total sales of consumables.
- Two XPS™ contracts were signed during the quarter.
- XVIVO has received Vinnova financing for cancer research in Europe.
- The Arbitration Board ruled that XVIVO does not have agreement rights to three Vivoline patents/ patent applications, pursuant to the improvement clause in the current agreement that the company has with Igelösa. The company's own products, STEEN Solution™, which is protected by patents that are valid until 2021, and Perfadex® are not part of the dispute.

THE PERIOD 2014 (JAN – DEC)

- Net sales in the period amounted to SEK 84.7 (68.9) million, corresponding to an increase of 23 percent.
- Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 15.7 million, corresponding to an EBITDA margin of 19 percent. One-time expenses of SEK 4.3 million related to the dispute regarding three Vivoline patents/patent applications have been charged against the period.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK 11.4 (13.0) million, corresponding to an EBITDA margin of 13 percent.
- Net income amounted to SEK 3.7 (8.1) million, resulting in earnings per share of SEK 0.18 (0.41).
- Cash flow from operating activities was SEK -3.7 (13.5) million and was affected by increased working capital of -10.5 SEK million and paid taxes of SEK -4.6 million.
- Net sales for consumables in the period amounted to SEK 83.2 (68.9) million, corresponding to an increase of 21 percent in SEK. Sales for consumables increased by 15 percent in local currency.
- Products for warm perfusion (STEEN Solution™ and products related to the use of the XPS™) accounted for 27 (16) percent of the total sales of consumables.
- XPS™ (Xvivo Perfusion System) received a CE mark, allowing XPS™ and the accompanying single-use products to be sold in Europe.
- The FDA granted marketing approval for XPS™ and STEEN Solution™, allowing STEEN Solution™, XPS™ and the accompanying single-use products to be sold in the US.
- XVIVO Perfusion completed a share issue through a private placement of SEK 73 million.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

- One XPS™ contract were signed after the end of the quarter.

CEO'S COMMENTS

2014 was XVIVO Perfusion's most successful year so far, where we passed several important milestones. The most important of these was the epoch-making FDA approval of STEEN Solution™ and XPS™. This constitutes a breakthrough for the entire transplantation industry, as it is the first approval of warm perfusion of organs in the USA, the world's largest market in the area. Other important milestones were the CE marking of XPS™, the first installation of an XPS™ outside the USA and not least the 23% increase in sales for the full year. These accelerated to +28% during the last quarter. The positive development of sales has been due to the rapid increase in sales of products for warm perfusion, which have doubled during the year, largely generated by the US approval. This strong development of sales has led to a continuing good gross margin and positive results, despite large investments in research and the building up of the organization during the year.

It was stimulating for the company to note the great interest in the share and thereby the confidence in the company at the time of the share issue during the summer. The financial strength that this share issue gives, together with the good clinical results demonstrated by STEEN Solution™, increases the chances of continued successful company development.

During the fourth quarter the Arbitration Board announced its decision in the dispute over the legal agreement between Igelösa and XVIVO Perfusion concerning three patents/patent applications. The ruling means that the Arbitration Board does not consider that XVIVO Perfusion has a right to these, despite the improvement clause in the current agreement that the company has with Igelösa. The decision clearly states that the case involved complex legal issues, where the Arbitration Board arrived at a different assessment than the patent and agreement experts that XVIVO has engaged. The company considers that the outcome is unfortunate, but wishes to emphasize that it does not impinge on the company's existing product portfolio or business focus. It is particularly important to mention that the company's own products, STEEN Solution™, which is protected by patents that have been granted and which are valid until 2021, and Perfadex® are not part of the dispute.

It is satisfying that interest in the XPS ™ and STEEN Solution ™ has increased further with the approval and launch in the US. Several clinics are next in line for introducing EVLP with the XPS ™ and STEEN Solution ™. Intensive efforts are underway to help the American clinics that already have an XPS™ to complete the necessary documentation required to be able to clinically use the products and obtain financial remuneration from Medicare. As from the registration in August, the US clinics pay for the products even if they are part of the study. A second focus has been the launch of XPS™ in Europe and a third the continuing development of new clinical indications for STEEN Solution™. It is assessed that the work in these areas of focus will have a good effect on sales during 2015.

XVIVO Perfusion's business concept, strategy and organization have been designed to give effective growth as well as considerable scalability without the need for heavy investments in infrastructure. We look forward to 2015 with confidence, as we have a unique product portfolio for warm perfusion which is clinically well documented, patented and approved by the regulatory authorities in all large markets and which is attracting great interest from clinics all over the world.

Magnus Nilsson
CEO

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, February 5, 2015.
Telephone: +44 (0) 1452 555566, enter code 56175829

FOURTH QUARTER 2014 (OCTOBER - DECEMBER)

NET SALES CONSUMABLES PER QUARTER (SEK MILLIONS)



NET SALES

XVIVO Perfusion's net sales of consumables* in the quarter amounted to SEK 25.5 (20.0) million, corresponding to an increase of 28 percent in SEK and an increase of 17 percent in local currency. Total net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding to an increase of 28 percent. Products for warm perfusion (STEEN Solution™ and products related to the use of the XPS™) accounted for 34 (21) percent of the total sales of consumables.

* See table on page 13 at the back of the report for product definitions.

COMPILATION OF NET SALES AND EBITDA

	January - September		July - September	
SEK THOUSANDS	2014	2013	2014	2013
Net Sales Consumables	**83 229**	**68 922**	**25 543**	**20 032**
Net Sales Durable Goods	1 473	0	0	0
Net Sales Total	84 702	68 922	25 543	20 032
Cost of Goods Consumables	**-19 187**	**-14 785**	**-5 937**	**-4 799**
Cost of Goods Durable goods	-1 469	0	0	0
Cost of Goods Total	-20 656	-14 785	-5 937	-4 799
Gross income Consumables	**64 042**	**54 137**	**19 606**	**15 233**
Gross margin Consumables, %	**77%**	**79%**	**77%**	**76%**
Gross income Durable Goods	4	0	0	0
Gross income Total	64 046	54 137	19 606	15 233
Gross margin Total , %	76%	79%	77%	76%
Costs before depreciation and amortization				
Selling expenses	-22 669	-17 051	-5 794	-4 707
Administrative expenses	-10 842	-11 805	-2 970	-3 028
Research and development costs	-19 455	-13 224	-7 931	-4 694
Other operating revenues and expenses	334	901	196	178
EBITDA	**11 414**	**12 958**	**3 107**	**2 982**
EBITDA in relation to Net Sales Consumables, %	**14%**	**19%**	**12%**	**15%**
EBITDA in relation to Total Net Sales , %	13%	19%	12%	15%
Amortization and Depreciation	-4 726	-2 184	-2 808	-365
Operating income	**6 688**	**10 774**	**299**	**2 617**

INCOME
Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.1 (3.0) million, corresponding to an EBITDA margin of 12 percent. One-time expenses of SEK 2.8 million related to the dispute regarding three Vivoline patents/patent applications have been charged against the quarter. EBITDA excluding one-time expenses amounted to SEK 5.9 million, corresponding to an EBITDA margin of 23 percent.

The gross margin for consumables during the quarter was 77 (76) percent. The total gross margin during the quarter was 77 (76) percent.

Selling expenses in relation to sales were 23 (23) percent. During the quarter additional resources have been invested in the continued establishment of STEEN Solution™ and XPS™ in the US and Europe. R&D costs were 42 (25) percent of sales. The increase is mainly due to amortization of the US STEEN Solution™ asset amounting to SEK 2.4 million and legal one-time expenses of SEK 2.8 million. Administrative expenses decreased to 12 (15) percent, mainly due to economies of scale. Net other operating revenues and expenses during the quarter were SEK 0.2 (0.2) million. During the period, SEK 1.1 million (6.6) of the development costs for STEEN Solution™ were capitalized as an intangible asset. The whole sum is attributable to the continued NOVEL study with the aim of PMA approval. Depreciation and amortization for the period amounted to SEK 2.8 million (0.4), of which SEK 2.4 million is amortization of the FDA HDE approval.

CASH FLOW
Cash flow from operating activities amounted to SEK -5.4 (7.1), mainly due to increased working capital affecting cash flow by SEK -7.8 million. Investments amounted to SEK 1.6 (6.7) million, of which SEK 1.1 (6.6) million was invested in the continued NOVEL study with the aim of PMA approval. The cash flow from financing activities was SEK 0.0 (0.7) million. Cash and cash equivalents at the end of the quarter amounted to SEK 48.2 (4.1) million.

FINANCING
XVIVO Perfusion's total credit facilities consist of an overdraft facility that at the end of the quarter amounted to SEK 20 (15) million, of which SEK 0.0 (6.7) million was utilized. The equity/assets ratio was 87 (76) percent at the end of the quarter.

OUTCOME OF THE ARBITRATION PROCEEDINGS AGAINST IGELÖSA
Just over a year ago XVIVO Perfusion AB (publ) initiated legal proceedings against Stig Steen/Igelösa and Vivoline Medical AB (publ) in order to determine whether three patents/patent applications that Vivoline had acquired from Stig Steen/Igelösa are in fact covered by the exclusive rights that XVIVO Perfusion has obtained from Stig Steen/Igelösa. In December the Arbitration Board ruled that XVIVO Perfusion does not have agreement rights to three Vivoline patents/patent applications, pursuant to the improvement clause in the current agreement that the company has with Igelösa. District Court proceedings against Vivoline Medical AB (publ) are ongoing. The dispute and the decision do not impinge on the company's existing product portfolio or business focus. The company's own products, STEEN Solution™, which is protected by patents that have been granted and which are valid until 2021, and Perfadex® are not part of the dispute.

THE PERIOD 2014 (JANUARY – DECEMBER)

NET SALES
XVIVO Perfusion's net sales of consumables in the period amounted to SEK 83.2 (68.9) million, corresponding to an increase of 21 percent in SEK and an increase of 15 percent in local currency. Total net sales in the period amounted to SEK 84.7 (68.9) million, corresponding to an increase of 23 percent. Products for warm perfusion (STEEN Solution™ and products related to the use of the XPS™) accounted for 27 (16) percent of the total sales of consumables.

NET SALES CONSUMABLES, ROLLING 12 MONTHS (SEK MILLIONS)*



INCOME
Operating income before depreciation and amortization (EBITDA) amounted to SEK 11.4 (13.0) million, corresponding to an EBITDA margin of 13 percent. One-time expenses of SEK 4.3 million related to the dispute regarding three Vivoline patents/patent applications have been charged against the period. EBITDA excluding one-time expenses amounted to SEK 15.7 million, corresponding to an EBITDA margin of 19 percent.

* Q4 2012 and quarters thereafter are XVIVO Perfusion's sales. All previous quarters derive from Vitrolife's Transplantation segment, as reported in Vitrolife's reporting.

The gross margin for consumables during the period was 77 (79) percent. The total gross margin during the period was 76 (79) percent.

Selling expenses in relation to sales were 27 (25) percent. The increase is due to additional resources supporting the continued establishment of STEEN Solution™ and XPS™ in the US and Europe. R&D costs were 28 (22) percent of sales. The increase is mainly due to expenses related to CE marking of XPS™, expenses related to research into new indications as well as amortization of the US STEEN Solution™ asset amounting to SEK 3.3 million and legal one-time expenses of SEK 4.3 million. Administrative expenses decreased to 13 (17) percent due to economies of scale. Net other operating revenues and expenses during the quarter were SEK 0.3 (0.9) million. During the period, SEK 14.5 million (12.1) of the development costs for the STEEN Solution™ FDA approval were capitalized as an intangible asset, of which SEK 13.4 million is attributable to the FDA HDE approval. The increase comes mainly from costs related to the FDA expert panel meeting and costs related to the FDA approval. Depreciation and amortization for the period amounted to SEK 4.7 million (2.2), of which 3.3 is amortization of the FDA HDE approval.

CASH FLOW
Cash flow from operating activities amounted to SEK -3.7 (13.5) million during the period affected by increased working capital of SEK -10.5 million and paid taxes SEK -4.6 million. Investments amounted to SEK 15.4 (14.9) million, of which SEK 14.5 (12.1) million was invested in the STEEN Solution™ study in the US. The cash flow from financing activities was SEK 62.7 (-2.3) million and consisted of a new share issue of SEK 69.2 million and decreased use of the overdraft facility of SEK 6.7 million.. Cash and cash equivalents at the end of the period amounted to SEK 48.2 (4.1) million.

REGULATORY APPROVAL OF XPS™ IN EUROPE
In March, 2014 the company obtained a CE mark for XPS™ (Xvivo Perfusion System), its newly developed system for lung perfusion. This allows XPS™ and the accompanying single-use products to be sold in Europe. XPS™ has been used with good clinical results at leading centers in the US. Ex vivo lung perfusion (EVLP) with STEEN Solution™ has been used in more than 300 lung transplants at almost 30 centers, including Vienna, Paris, Toronto and others.

FDA APPROVAL OF XPS™ AND STEEN SOLUTION™ IN THE US
On August 12, 2014 XVIVO received HDE (Humanitarian Device Exemption) approval from the FDA for the products XPS™ and STEEN Solution™ for sale on the American market. The approval, which is the first in the USA for warm perfusion of organs outside the body pending transplantation, means that STEEN Solution™, XPS™ and the accompanying single-use articles are the only medical device products that may be legally sold for Ex Vivo Lung Perfusion (EVLP) of initially unacceptable donated lungs at body temperature. Just over 40 percent of all lung transplantations worldwide are carried out in the USA.

PRIVATE PLACEMENT
During the period XVIVO Perfusion completed a share issue through private placement of SEK 73 million directed to a group of qualified Swedish and international investors in order to facilitate a faster build-up of the company's working capital for the US and European launch of XPS™ and STEEN Solution™ and also for investment in new indications. The private placement will increase the number of shares and votes in XVIVO Perfusion by 1,950,000, from 19,562,769 to 21,512,769. The share capital increased by SEK 49,840 to SEK 549,840.

OUTLOOK FOR 2014

As the number of lungs that can be transplanted using traditional cold perfusion cannot be predicted to increase more than the number of lungs donated, it is expected that growth will come primarily from warm perfusion using the STEEN Solution™ method. The focus during 2015 is therefore to establish the STEEN Solution™ method as the standard treatment for lung transplantation. We see increased interest in Europe and Australia for the XPS™ system and the focus will be on the XPS™ launch, as well as on establishing the STEEN Solution™ method at more clinics by means of the good clinical results demonstrated so far. Approximately five percent of the total number of lung transplants in the world today are carried out in Asia, the Middle East and Eastern Europe, but with greater economic strength the number of lung transplants will increase. By establishing the STEEN Solution™ method early in these markets, this development can be more rapid than would otherwise have been possible.

In the USA the main focus will be on the launch of STEEN Solution™ and XPS™ and above all on as many clinics as possible gaining access to and beginning to use XPS™ and warm perfusion with STEEN Solution™ clinically. Resources for sales and marketing in the USA will be increased to establish the STEEN Solution™ technology, and this is expected to contribute positively to sales during 2015. Amortization of the capitalized expenses for STEEN Solution's™ HDE approval will be charged against income during 2015 to the tune of SEK 9.8 million. The clinical NOVEL study will continue with the goal of attaining PMA approval in the American market (current approval is a so-called HDE, Humanitarian Device Exemption). The clinics included in the study will pay full price for products. Expenses for the company related to documenting the results of this PMA study will be capitalized on an ongoing basis.

Lung availability is also the limiting factor for increasing the number of transplantations of other organs than lungs. The focus of research and development is therefore on developing the use of the STEEN Solution™ method for more indications and on developing other similar areas of use such as the warm perfusion of organs still in the body.

THE COMPANY IN BRIEF

OPERATIONS

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation. Today, the company's product Perfadex® has a market share of more than 90 percent in the traditional preservation of lungs for transplantation. The company's products XPS™ and STEEN Solution™ for warm perfusion are the only products on the market that have FDA approval for warm perfusion of lungs in the US.

A great problem in transplantation healthcare is the lack of available lungs. Currently in the USA, only around 20 percent of the available donated lungs are transplanted as it is considered far too risky to transplant the remaining majority. By using XVIVO's product STEEN Solution™, the organ is cleared of harmful substances from the donor, thus creating a better environment for the organ's cells. The technology thereby allows the organ to "recover" when possible. It also allows for functional testing to be performed outside the body. In clinical use in Europe, Australia and Canada, and in a clinical trial in the USA, it has emerged that once STEEN Solution™ perfusion has been carried out, many of the organs that were initially "refused" are assessed as being usable and have been successfully transplanted into patients with end stage lung disease. Therefore the use of STEEN Solution™ has the potential to increase the total number of lung transplants.

Over the years, XVIVO has established close relationships with most of the world's lung transplant centers and has made Perfadex® a completely dominant product in its niche. XVIVO intends to make STEEN Solution™ available all over the world with the firm conviction that the number of transplants will increase as healthcare systems gain knowledge of and access to STEEN Solution™. The objective of the company is to create value for both patients and shareholders by providing a unique product in a market with great growth potential.

BUSINESS CONCEPT

XVIVO Perfusion's business concept is to increase the survival rate of patients in need of an organ transplant by providing effective products that increase the availability and survival potential of organs once transplanted.

VISION

The company's vision is that no one should have to die waiting for a new organ.

OBJECTIVE

The company's objective is to establish the warm perfusion of organs with STEEN Solution™ as the standard treatment in the transplantation of lungs and other organs.

STRATEGY

XVIVO Perfusion's strategy focuses on getting lung evaluation outside the body using the STEEN Solution™ method accepted as a standard procedure. A basic precondition of the strategy is to obtain regulatory approval for STEEN Solution™ in all important markets. XVIVO Perfusion has demonstrated through published preclinical and clinical studies that warm perfusion of organs using the STEEN Solution™ method results in more available organs, thereby giving more patients the potential to have a life-saving treatment, better quality of life, socioeconomic gains, and lower morbidity and mortality. Furthermore, the company will strive to increase awareness of the STEEN Solution™ method in important groups of stakeholders and will work with key opinion leaders in the area.

OTHER INFORMATION

ORGANIZATION AND PERSONNEL

At the end of quarter the number of employees was sixteen, of whom seven were women and nine were men. Of these, eleven people were employed in Sweden and five in the USA. In addition, the company uses five consultants.

INFORMATION ON TRANSACTIONS WITH RELATED PARTIES

No transactions that have substantially affected the company's results and financial position have been carried out with related parties during the quarter.

RISK MANAGEMENT

XVIVO Perfusion is constantly working to identify, evaluate, and manage risks in different systems and processes. Risk analyses are performed continually with regard to the company's normal business activities and also in connection with activities that are outside XVIVO Perfusion's regular quality system. The most important strategic and operative risks affecting the company are described in the 2013 annual report.

SEASONAL EFFECTS

XVIVO Perfusion's sales are marginally affected by seasonal effects. There is slightly less activity during the summer months.

EVENTS AFTER THE END OF THE REPORTING PERIOD

No events have occurred after the end of the reporting period that significantly affect the assessment of the financial information in this report.

ELECTION COMMITTEE

The following persons have been appointed as members of XVIVO Perfusion's Election Committee for the 2015 Annual General Meeting:

Gösta Johannesson, representing Bure Equity AB,
Thomas Olausson
Martin Lewin, representing Eccenovo AB,

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company Election Committee which were determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on April 29, 2014.

Shareholders who wish to have a matter considered at the Annual General Meeting can make a request to the Board to this effect. Such a request concerning consideration of a matter should be sent to XVIVO Perfusion AB (publ), Att: Chairman of the Board, Box 53015, S-400 14 Göteborg, Sweden, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or in any case in such good time that the matter, if necessary, can be included in the invitation to attend the meeting.

ANNUAL GENERAL MEETING AND ANNUAL REPORT

The Annual General Meeting will be held on Thursday April 23, 2015, at 4 pm at XVIVO Perfusion's premises in Gothenburg, visitors' address Mässans gata 10. Shareholders will be invited to attend through an announcement in the Swedish Official Gazette and through information in Dagens Industri that shareholders have been invited to attend, no earlier than six weeks and no later than four weeks before the meeting.

It is estimated that XVIVO Perfusion's Annual Report for 2014 will be available for download on XVIVO Perfusion's website during the week commencing Monday, March 30.

February 5, 2015
Gothenburg

The Board

THIS REPORT HAS NOT BEEN REVIEWED BY THE COMPANY'S AUDITORS.

FINANCIAL REPORTS

XVIVO Perfusion's interim reports are published on the company's website, www.xvivoperfusion.com.

Interim report January-March: Wednesday April 22
Interim report April-June: Thursday August 13
Interim report July-September: Thursday October 23

FOR FURTHER INFORMATION, PLEASE CONTACT

Magnus Nilsson, CEO, tel: +46 31 788 21 50,
e-mail: magnus.nilsson@xvivoperfusion.com

Christoffer Rosenblad, CFO, tel: +46 31 788 21 59,
e-mail: christoffer.rosenblad@xvivoperfusion.com

The Certified Adviser is Redeye, www.redeye.se
Certified Adviser är Redeye, www.redeye.se

XVIVO Perfusion is required to publish the information in this report in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on February 5, 2015 at 8.30 am.

This is a translation of the Swedish version of the report. When in doubt, the Swedish wording prevails.

CONSOLIDATED INCOME STATEMENTS

SEK THOUSANDS	Januari - December 2014	2013	October - December 2014	2013
Net sales	84 702	68 922	25 543	20 032
Cost of goods sold	-20 656	-14 785	-5 937	-4 799
Gross income	**64 046**	**54 137**	**19 606**	**15 233**
Selling expenses	-22 669	-17 051	-5 794	-4 707
Administrative expenses	-11 102	-12 019	-3 034	-3 090
Research and development costs	-23 921	-15 194	-10 675	-4 997
Other operating revenues and expenses	334	901	196	178
Operating income	**6 688**	**10 774**	**299**	**2 617**
Financial income and expenses	28	-56	166	345
Income after financial items	**6 716**	**10 718**	**465**	**2 962**
Taxes	-2 978	-2 664	-777	-598
Net income	**3 738**	**8 054**	**-312**	**2 364**
Attributable to				
Parent Company's shareholders	3 738	8 054	-312	2 364
Earnings per share, SEK	0,18	0,41	-0,01	0,12
Earnings per share, SEK*	0,18	0,41	-0,01	0,12
Average number of outstanding shares	20 537 769	19 562 769	21 512 769	19 562 769
Average number of outstanding shares*	20 732 769	19 562 769	21 707 769	19 562 769
Number of shares at closing day	21 512 769	19 562 769	21 512 769	19 562 769
Number of shares at closing day*	21 707 769	19 757 769	21 707 769	19 757 769
EBITDA	**11 414**	**12 958**	**3 107**	**2 982**
Amortization	-4 466	-1 970	-2 744	-303
Depreciation	-260	-214	-64	-62
Operating income	**6 688**	**10 774**	**299**	**2 617**

* After dilution. 21 512 769 + 195 000 = 21 707 769. See note 2 for information on warrant programs
The net present value of the issue price of 195 000 warrants in the 2013/2015 warrant program is lower than the share price at closing day and than the average share price for the period.

CONSOLIDATED BALANCE SHEETS

SEK THOUSANDS	Dec 31, 2014	Dec 31, 2013
ASSETS		
Goodwill	2 206	3 008
Other intangible fixed assets	97 135	86 214
Tangible fixed assets	1 124	917
Financial fixed assets	8 094	4 405
Inventories	26 189	17 990
Accounts receivable	12 194	7 518
Other current receivables	6 556	3 382
Liquid funds	48 203	4 131
Total assets	**201 701**	**127 565**
SHAREHOLDERS' EQUITY AND LIABILITIES		
Shareholders' equity, attributable to the Parent Company's shareholders	176 183	96 635
Provisions	6 760	5 272
Accounts payable	6 468	8 419
Overdraft	0	6 659
Current tax liabilities	3 531	3 212
Other short-term liabilities	1 129	458
Accrued expenses and prepaid income	7 630	6 910
Total shareholders' equity and liabilities	**201 701**	**127 565**
Pledged assets for own liabilities	20 250	15 250
Contingent liabilities	-	-

CONSOLIDATED KEY RATIOS

	Januari - December		October - December	
SEK THOUSANDS	2014	2013	2014	2013
Gross Margin Consumables, %	77	79	77	76
Gross margin, %	76	79	77	76
Operating margin before R&D costs, %	36	38	43	38
EBITDA portion of net sales consumables, %	14	19	12	15
EBITDA, %	13	19	12	15
Operating margin, %	8	16	1	13
Net margin, %	4	12	-1	12
Equity/assets ratio, %	87	76	87	76
Return on equity, %	3	9	0	2
Income per share, SEK	0,18	0,41	-0,01	0,12
Shareholders' equity per share, SEK	8,19	4,94	8,19	4,94
Share price on closing day, SEK	34,30	33,50	34,30	33,50

CONSOLIDATED CASH FLOW STATEMENTS

	Januari - December		October - December	
SEK THOUSANDS	2014	2013	2014	2013
Income after financial items	6 716	10 718	465	2 962
Adjustment for items not affecting cash flow	4 664	1 992	2 646	80
Paid taxes	-4 590	-978	-750	-254
Change in inventories	-5 481	-4 636	-3 651	409
Change in trade receivables	-6 797	473	-6 260	-2 552
Change in trade payables	1 747	5 895	2 103	6 425
Cash flow from operating activities	**-3 741**	**13 464**	**-5 447**	**7 070**
Cash flow from investing activities	-15 361	-14 852	-1 647	-6 711
Cash flow from financing activities	62 697	-2 303	0	685
Cash flow for the period	**43 595**	**-3 691**	**-7 094**	**1 044**
Liquid funds at beginning of period	4 131	7 776	55 064	2 962
Exchange rate difference in liquid funds	477	46	233	125
Liquid funds at end of period	**48 203**	**4 131**	**48 203**	**4 131**

CONSOLIDATED CHANGES IN SHAREHOLDERS' EQUITY

	Attributable to Parent Company's shareholders				
SEK THOUSANDS	Share capital	Reserves	Other paid in capital	Retained earnings incl. profit for the year	Sum shareholders' equity
Opening balance January 1, 2013	**500**	**4 925**	**84 141**	**-801**	**88 765**
Total net income				8 054	8 054
Tax allocation reserve		1 521		-1 521	0
Share warrant program			127		127
Change in currency diff. subsidiary				-311	-311
Closing balance December 31, 2013	**500**	**6 446**	**84 268**	**5 421**	**96 635**
Opening balance January 1, 2014	**500**	**6 446**	**84 268**	**5 421**	**96 635**
Total net income				3 738	3 738
Tax allocation reserve		3 120		-3 120	0
Share warrent program			216		216
New issue of shares in registration	50		69 139		69 189
Change in currency diff. subsidiary				6 405	6 405
Closing balance September 30, 2014	**550**	**9 566**	**153 623**	**12 444**	**176 183**

CONSOLIDATED INCOME STATEMENTS PER QUARTER

SEK THOUSANDS	Oct - Dec 2014	July - Sep 2014	April - June 2014	Jan - March 2014	Oct - Dec 2013	July - Sep 2013	April - June 2013	Jan - March 2013
Net sales	25 543	22 427	18 474	18 258	20 032	16 784	15 777	16 329
Cost of goods sold	-5 937	-6 474	-3 863	-4 382	-4 799	-3 409	-3 327	-3 250
Gross income	**19 606**	**15 953**	**14 611**	**13 876**	**15 233**	**13 375**	**12 450**	**13 079**
Selling expenses	-5 794	-5 586	-6 313	-4 976	-4 707	-4 352	-4 719	-3 273
Administrative expenses	-3 034	-2 495	-3 023	-2 550	-3 090	-2 643	-2 942	-3 344
Research and development costs	-10 675	-5 661	-4 012	-3 573	-4 997	-4 513	-2 887	-2 797
Other operating revenues and expenses	196	52	125	-39	178	825	101	-203
Operating income	**299**	**2 263**	**1 388**	**2 738**	**2 617**	**2 692**	**2 003**	**3 462**
Financial income and expenses	166	36	-81	-93	345	-512	275	-164
Income after financial items	**465**	**2 299**	**1 307**	**2 645**	**2 962**	**2 180**	**2 278**	**3 298**
Taxes	-777	-822	-555	-824	-598	-604	-565	-898
Net income	**-312**	**1 477**	**752**	**1 821**	**2 364**	**1 576**	**1 713**	**2 400**
Attributable to								
Parent Company's shareholders	-312	1 477	752	1 821	2 364	1 576	1 713	2 400
Earnings per share, SEK	-0,01	0,07	0,04	0,09	0,12	0,08	0,09	0,12
Earnings per share, SEK*	-0,01	0,07	0,04	0,09	0,12	0,08	0,09	0,12
Average number of outstanding shares	21 512 769	21 512 769	19 562 769	19 562 769	19 562 769	19 562 769	19 562 769	19 562 769
Average number of outstanding shares*	21 707 769	21 707 769	19 757 769	19 757 769	19 562 769	19 562 769	19 562 769	19 562 769
Number of shares at closing day	21 512 769	21 512 769	19 562 769	19 562 769	19 562 769	19 562 769	19 562 769	19 562 769
Number of shares at closing day*	21 707 769	21 707 769	19 757 769	19 757 769	19 757 769	19 562 769	19 562 769	19 562 769
EBITDA	**3 107**	**3 445**	**1 756**	**3 106**	**2 982**	**3 828**	**2 352**	**3 796**
Amortization	-2 744	-1 116	-303	-303	-303	-1 073	-297	-297
Depreciation	-64	-66	-65	-65	-62	-63	-52	-37
Operating income	**299**	**2 263**	**1 388**	**2 738**	**2 617**	**2 692**	**2 003**	**3 462**

* After dilution. See note 2 for information on warrant programs

INCOME STATEMENTS FOR THE PARENT COMPANY

SEK THOUSANDS	Januari - December 2014	2013	October - December 2014	2013
Net sales	80 845	61 154	31 096	18 611
Cost of goods sold	-17 256	-16 810	-5 392	-7 059
Gross income	**63 589**	**44 344**	**25 704**	**11 552**
Selling expenses	-15 801	-12 597	-4 138	-3 389
Administrative expenses	-8 932	-10 016	-2 547	-2 535
Research and development costs	-23 149	-14 391	-10 804	-4 856
Other operating revenues and expenses	331	900	195	177
Operating income	**16 038**	**8 240**	**8 410**	**949**
Financial income and expenses	3 101	-363	1 961	37
Income after financial items	**19 139**	**7 877**	**10 371**	**986**
Year end dispositions	-4 000	-1 950	-4 000	-1 950
Taxes	-3 427	-1 314	-1 559	202
Net income	**11 712**	**4 613**	**4 812**	**-762**

Depreciation and amortization has reduced income for the period by SEK 3 807 thousand (1 280), of which SEK 2 575 thousand (137) for the quarter.

BALANCE SHEETS FOR THE PARENT COMPANY

SEK THOUSANDS	Dec 31, 2014	Dec 31, 2013
ASSETS		
Balanced expenditures for development	95 908	84 904
Patents and licencies	1 202	1 270
Trademarks	25	30
Tangible fixed assets	338	419
Participation in affiliated companies	14 475	14 475
Other financial fixed assets	4 099	2 784
Inventories	7 716	5 315
Accounts receivable	5 431	3 641
Receivables from affiliated companies	24 737	6 883
Other current receivables	6 334	3 162
Liquid funds	44 060	2 568
Total assets	**204 325**	**125 451**
SHAREHOLDERS' EQUITY AND LIABILITIES		
Shareholders' equity	172 745	91 627
Untaxed reserves	12 238	8 238
Provisions	4 068	3 459
Overdraft	0	6 659
Accounts payable	4 524	6 899
Liabilities to affiliated companies	118	-
Current tax liabilities	3 417	2 490
Other short-term liabilities	7 215	6 079
Total shareholders' equity and liabilities	**204 325**	**125 451**
Pledged assets for own liabilities	20 250	15 250
Contingent liabilities	-	-

NOTE 1. ACCOUNTING PRINCIPLES

This interim report was prepared pursuant to the Swedish Annual Accounts Act. Effective January 1, the company applies framework BFNAR 2012-1 from the Swedish Accounting Standards Board (K3). The transition to K3 has had no impact on the financial statements.

NOTE 2. WARRANT PROGRAM

Share warrant program 2013/2015 consists of 195,000 warrants with subsequent rights to subscribe for new shares (corresponding to 195,000 shares). If all the warrants are exercised the share capital will increase by around SEK 5,000, corresponding to dilution of approximately 0.9 percent of the total number of shares and votes. In June 2015 each warrant will entitle the holder to subscribe for one new share at a price of SEK 32.40.

On April 29, 2014 the annual meeting of shareholders in XVIVO Perfusion AB resolved to issue 195,000 warrants (corresponding to 195,000 shares) to the company's employees. In June 2016 each warrant will entitle the holder to subscribe for one new share at a price of SEK 58.60. If all the warrants are exercised the share capital will increase by around SEK 5,000, corresponding to dilution of approximately 0.9 percent of the total number of shares and votes.

In total there are 390,000 outstanding warrants in two programs. If all the warrants are exercised to subscribe for shares, the share capital will increase by around SEK 10,000 and the number of shares will increase by 390,000 shares in total, corresponding to dilution of approximately 1.8 percent of the total number of shares and votes.

	PRODUCT NAME	SALES TYPE	SALES AREA
	**XPS™**	Capital Goods	Machine for Warm Perfusion
	**STEEN Solution™**	Consumable	Warm Perfusion
	**XPS Disposable Lung Perfusion Circuit™**	Consumable	Warm Perfusion
	XPS Disposable Lung Kit™	Consumable	Warm Perfusion
	**Organ Chamber™**	Consumable	Warm Perfusion
	**XPS PGM Disposable Sensors™**	Consumable	Warm Perfusion
	**Perfadex®**	Consumable	Cold Preservation
	**Silicone Tubing Set**	Consumable	Cold Preservation

WWW.XVIVOPERFUSION.COM

XVIVO Perfusion AB, Box 53015, SE-400 14 Göteborg, Sweden, Tel +46-31-788 21 50, Fax +46-31-788 21 69, info@xvivoperfusion.com
XVIVO Perfusion Inc., 3666 South Inca St, Englewood, CO 80110, USA, Tel: +1 303 395 9171, Fax: +1 800 694 5897